Objective: Cardiovascular Implantable Electronic Devices (CIEDs) are used extensively for treating life-threatening conditions such as bradycardia, atrioventricular block and heart failure. The complicated heterogeneous physical dynamics of patients provide distinct challenges to device development and validation. We address this problem by proposing a device testing framework within the in-silico closed-loop context of patient physiology.
Methods: We develop an automated framework to validate CIEDs in closed-loop with a high-level physiologically based computational heart model. The framework includes test generation, execution and evaluation, which automatically guides an integrated stochastic optimization algorithm for exploration of physiological conditions.
Conclusion: The results show that using a closed loop device-heart model framework can achieve high system test coverage, while the heart model provides clinically relevant responses. The simulated findings of pacemaker mediated tachycardia risk evaluation agree well with the clinical observations. Furthermore, we illustrate how device programming parameter selection affects the treatment efficacy for specific physiological conditions.
Significance: This work demonstrates that incorporating model based closed-loop testing of CIEDs into their design provides important indications of safety and efficacy under constrained physiological conditions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/JBHI.2019.2947007 | DOI Listing |
J Cardiovasc Electrophysiol
January 2025
McGill University Health Centre, Montreal, Canada.
Background: Electrographic flow (EGF) mapping allows for the visualization of global atrial wavefront propagations. One mechanism of initiation and maintenance of atrial fibrillation (AF) is stimulation from EGF-identified focal sources that serve as driver sites of fibrillatory conduction. Electrographic flow consistency (EGFC) further quantifies the concordance of observed wavefront patterns, indicating that a healthier substrate shows more organized wavefront propagation and higher EGFC.
View Article and Find Full Text PDFClin Cardiol
January 2025
National Heart and Lung Institute, Imperial College London, London, UK.
Background: Parkinson disease (PD) and cardiovascular diseases (CVD) present significant health burdens, particularly among older adults. Patients with PD have an elevated risk of CVD-related mortality. Analyzing mortality trends in this population may help guide focused interventions.
View Article and Find Full Text PDFJ Am Heart Assoc
January 2025
Department of Population Health Sciences Weill Cornell Medicine New York NY.
Background: Transport by mobile stroke units (MSUs), which provide access to computed tomography scanning and intravenous blood pressure medications and thrombolytics, reduces time to treatment and may improve short-term functional outcomes for patients with acute stroke. The longer-term clinical and financial impacts remain incompletely understood. The aim of the study was to determine whether MSU care is associated with better health, utilization, and spending outcomes for patients with suspected acute stroke.
View Article and Find Full Text PDFArterioscler Thromb Vasc Biol
January 2025
Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston. (B.C.-C., N.A.V.G., N.L.P., L.P.E., V.S.K.S., A.M.O., J.L., G.M., O.H., A.D., S.W.Y., C.A.I., K.C.O.M., S. Kotla, J.-i.A.).
Modulating immune function is a critical strategy in cancer and atherosclerosis treatments. For cancer, boosting or maintaining the immune system is crucial to prevent tumor growth. However, in vascular disease, mitigating immune responses can decrease inflammation and slow atherosclerosis progression.
View Article and Find Full Text PDFJACC Adv
December 2024
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Background: Rheumatic atrial fibrillation (AF) patients are at an elevated risk of stroke events, yet the associated risk factors remain unclear.
Objectives: This study aimed to evaluate the effectiveness of the CHADS-VASc score in predicting stroke events in rheumatic AF patients and explore potential enhancements for increased predicting accuracy in the Asian population, comparing it to nonvalvular AF.
Methods: A retrospective cohort study spanning March 2010 to December 2020 included 29,341 AF patients followed up for up to 10 years, with 1,942 identified as having rheumatic AF.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!